Abstract 373P
Background
The immunonutritional background has been deeply implicated in cancer behavior and clinical outcomes. Here, we explored the prognostic impact of the Controlling Nutritional Status (CONUT) score through its correlation with blood immunophenotypes and cytokines to provide an easily available non-invasive tool to predict the survival benefit from chemo-immunotherapy (CT-IO) in metastatic NSCLC (mNSCLC).
Methods
From a prospective cohort of mNSCLC patients (pts) treated with CT-IO, we collected clinicopathological data and baseline blood samples for the assessment of CONUT score (albumin, lymphocytes, total cholesterol), relevant immunophenotypes (flow-cytometry) and cytokines (multiplex array). Correlations of CONUT with survival outcomes (progression-free/overall survival, PFS/OS) and circulating immune-inflammatory benchmarks were analyzed.
Results
Overall, 81 consecutive mNSCLC pts were enrolled; at a median follow-up of 27.4 months (95% CI 23.2–30.5), those with a low (
Conclusions
A good nutritional status at baseline (CONUT < 3), relevantly associated with an effective immune response, might represent a suitable predictor of better survival outcomes in pts with mNSCLC treated with CT-IO.
Legal entity responsible for the study
The authors
Funding
AIRC - Italian Association for Cancer Research
Disclosure
All authors have declared no conflicts of interest.